| 11.12 2.82 (33.98%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 13.18 |
1-year : | 15.4 |
| Resists | First : | 11.28 |
Second : | 13.18 |
| Pivot price | 7.35 |
|||
| Supports | First : | 7.02 |
Second : | 4.38 |
| MAs | MA(5) : | 8.4 |
MA(20) : | 6.79 |
| MA(100) : | 4.84 |
MA(250) : | 0 | |
| MACD | MACD : | 1 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 96.9 |
D(3) : | 92.6 |
| RSI | RSI(14): 92.5 |
|||
| 52-week | High : | 11.28 | Low : | 2.75 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ALMS ] has closed above the upper band by 24.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 335% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.29 - 11.33 | 11.33 - 11.37 |
| Low: | 8.34 - 8.38 | 8.38 - 8.42 |
| Close: | 11.04 - 11.11 | 11.11 - 11.17 |
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Thu, 04 Dec 2025
Alumis Inc (ALMS) director Akkaraju buys shares worth $2m - Investing.com
Tue, 25 Nov 2025
Tananbaum James B. buys Alumis Inc (ALMS) stock worth $532924 - Investing.com
Wed, 19 Nov 2025
Foresite Labs buys Alumis Inc (ALMS) shares worth $3.09 million - Investing.com
Wed, 19 Nov 2025
Alumis Inc (ALMS) director Akkaraju buys shares worth $1.53 million - Investing.com
Wed, 19 Nov 2025
Alumis Inc: director Tananbaum buys $3.09 million in ALMS stock - Investing.com
Mon, 17 Nov 2025
Alumis Inc: director Akkaraju buys $1.45 million in shares - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 97 (M) |
| Held by Insiders | 6.563e+007 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 2,110 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.3933e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 372.3 % |
| Return on Equity (ttm) | -61.5 % |
| Qtrly Rev. Growth | 2.212e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -372 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 3.53e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|